Figure 3.

Biomarker analysis over time using different methods for evaluation and comparison. A-C) Fold change (calculated for each patient as ratio of measured value over value at baseline) analysis plotted for various cell populations and cell surface markers. Mean fold changes for all patients from baseline of day −9 with standard error are shown. At base of panel C), administration days for doses of G-CSF (G), plerixafor (P), busulfan-fludarabine (BuFlu) are shown (see Figure 1 for complete details). Fold changes for A: white blood cells (WBCs) and blasts; B: CXCR4+, CD34+, and VLA-4+ cells; C: FISH+ and FISH- cells for patients with informative cytogenetics; D) Longitudinal analysis using a random effect model (see Supplementary Table 7) of estimated mean WBC as a function of time, with 95% confidence bands, for the 4 strata based on disease status at time of transplant and cytogenetics, using mean age and mean log (BM blasts): (1) (upper left) Non-CR with unfavorable cytogenetics, (2) (upper right) Non-CR with intermediate/favorable cytogenetics, (3) (lower left) CR with unfavorable cytogenetics, and (4) (lower right) CR with intermediate/favorable cytogenetics; E-F) Change in mean fluorescence intensity (MFI) of CXCR4 (level of CXCR4 surface expression) during conditioning. E) Mean MFI with standard error over time (* denotes p-value < 0.05, ** denotes p-value < 0.01). F) Scatter plot showing each patient's CXCR4 MFI. Values shown for all p-values < 0.1. At base of panels E) and F), administration days for doses of G-CSF (G), plerixafor (P), busulfun-fludarabine (BuFlu) are shown (see Figure 1 for complete details).